**DESCRIPTION**

**Species Reactivity**  Human

**Specificity**  Detects human Endoglin/CD105.

**Source**  Monoclonal Mouse IgG1, Clone # 166707

**Purification**  Protein A or G purified from hybridoma culture supernatant

**Immunogen**  Mouse myeloma cell line NS0-derived recombinant human Endoglin/CD105

Glu26-Gly586

Accession # Q5T9B9

**Formulation**  Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. See Certificate of Analysis for details.

*Small pack size (-SP) is supplied either lyophilized or as a 0.2 μm filtered solution in PBS.

**APPLICATIONS**

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

<table>
<thead>
<tr>
<th>Recommended Concentration</th>
<th>Sample</th>
</tr>
</thead>
<tbody>
<tr>
<td>Flow Cytometry</td>
<td>0.25 μg/10^6 cells</td>
</tr>
<tr>
<td>CyTOF-ready</td>
<td>Ready to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation.</td>
</tr>
</tbody>
</table>

**DATA**

Detection of Endoglin/CD105 in U937 Human Cell Line by Flow Cytometry. U937 human histiocytic lymphoma cell line was stained with Mouse Anti-Human Endoglin/CD105 Monoclonal Antibody (Catalog # MAB10971, filled histogram) or isotype control antibody (Catalog # MAB002, open histogram), followed by Phycoerythrin-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # F0102B). View our protocol for Staining Membrane-associated Proteins.

**PREPARATION AND STORAGE**

**Reconstitution**  Reconstitute at 0.5 mg/mL in sterile PBS.

**Shipping**  The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.

*Small pack size (-SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C

**Stability & Storage**  Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
**BACKGROUND**

Endoglin (CD105) is a 90 kDa type I transmembrane glycoprotein of the zona pellucida (ZP) family of proteins (1-3). Endoglin and betaglycan/TβRIII are type III receptors for TGF beta superfamily ligands, sharing 71% aa identity in the transmembrane (TM) and cytoplasmic domains. Endoglin is highly expressed on proliferating vascular endothelial cells, chondrocytes, and syncytiotrophoblasts of term placenta, with lower amounts on hematopoietic, mesenchymal and neural crest stem cells, activated monocytes, and lymphoid and myeloid leukemic cells (2-5). Human Endoglin cDNA encodes 658 amino acids (aa) including a 25 aa signal sequence, a 561 aa extracellular domain (ECD) with an orphan domain and a two-part ZP domain, a TM domain and a 47 aa cytoplasmic domain (1-3). An isoform with a 14 aa cytoplasmic domain (S-endoglin) can oppose effects of long (L) Endoglin (6, 7). The human Endoglin ECD shares 65-72% aa identity with mouse, rat, bovine, porcine and canine Endoglin. Endoglin homodimers interact with TGFβ1 and TGFβ3 (but not TGFβ2), but only after binding TβRII (8). Similarly, they interact with activin-A and BMP-7 via activin type IIa or B receptors, and with BMP-2 via BMPR-1A/ALK-3 or BMPR-1B/ALK-6 (9). BMP-9, however, is reported to bind Endoglin directly (10). Endoglin modifies ligand-induced signaling in multiple ways. For example, expression of Endoglin can inhibit TGFβ1 signals but enhance BMP7 signals in the same myoblast cell line (11). In endothelial cells, Endoglin inhibits TβRI/ALK5, but enhances ALK1-mediated activation (12). Deletion of mouse Endoglin causes lethal vascular and cardiovascular defects, and human Endoglin haploinsufficiency can cause the vascular disorder, hereditary hemorrhagic telangiectasia type I (13, 14). These abnormalities confirm the essential function of Endoglin in differentiation of smooth muscle, angiogenesis, and neovascularization (2-4, 12-14). In preeclampsia of pregnancy, high levels of proteolytically generated soluble Endoglin and VEGF R1 (sFLT1), along with low placental growth factor (PIGF), are pathogenic due to antiangiogenic activity (15).

**References:**